SUNITINIB (SUTENT) V PERVOY LINII LEChENIYa METASTATIChESKOGO RAKA POChKI
- Authors: Gutorov SL1, Borisova EI1, Lichinitser MR1
-
Affiliations:
- Issue: No 18 (2009)
- Pages: 31-34
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278115
- ID: 278115
Cite item
Full Text
Abstract
Представлены результаты клинических исследований эффективности сунитиниба при метастатическом раке почки. Показано, что в первой линии лечения сунитиниб по сравнению с интерфероном альфа достоверно повышает частоту достижения объективного эффекта (47 против 12 %), более чем в 2 раза увеличивает медиану времени до прогрессирования (11 против 4 месяцев). Эффективное лечение сунитинибом привело к увеличению медианы общей выживаемости больных до 26,4 месяца. Высокая лечебная эффективность и приемлемый спектр побочных эффектов позволяют рекомендовать сунитиниб как препарат выбора в первой линии лечения диссеминированного светлоклеточного рака почки.
References
- Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2007;57:43-66.
- Athar U, Gentile TC. Treatment options for metastatic renal cell carcinoma: a review. Can J Urol 2008;15(2):3954-66.
- Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-63.
- Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
- O'Farrell AM, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003;9:5465-76.
- Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
- Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008;26:5024.
- Larkin JMG, Kipps ELS, Powell CJ. et al. Systemic therapy for advanced renal cell carcinoma. Ther Adv Med Oncol 2009;1(1):15-27.
- Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96.
- Patil S, Figlin RA, Hutson TE, et al. Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2009;27(15S):abstr. 5042.
- Wang S, Ivanova J, Antras L, et al. Safety and treatment (trx) patterns of angiogenesis inhibitors (AIs) in patients (pts) with metastatic renal cell carcinoma (mRCC): evidence from US community oncology clinics. Eur J Cancer 2009;7(2 Suppl.):436.
- Cella D, Michaelson MD, Bushmakin AG, et al. Final quality of life (QOL) results with geographical analysis for sunitinib versus interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (mRCC). Eur J Cancer 2009;7(2):176.
- Lee S, Chung HC, Mainwaring P, et al. An Asian subpopulation analysis of the safety and efficacy of sunitinib in metastatic renal cell carcinoma. Eur J Cancer 2009;7(2 Suppl.):428, abstr. 7118.
- Barrios CH, Hernandez-Barajas D, Brown MP, et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma (mRCC): preliminary results. Eur J Cancer 2009;7(2 Suppl.):429, abstr. 7122.
Supplementary files
